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Abstract objective To assess the burden of posterior segment eye diseases (PSEDs) in sub-Saharan Africa (SSA).
methods We reviewed published population-based data from SSA and other relevant populations
on the leading PSED, specifically glaucoma, diabetic retinopathy and age-related macular
degeneration, as causes of blindness and visual impairment in adults. Data were extracted from
population-based studies conducted in SSA and elsewhere where relevant.
results PSEDs, when grouped or as individual diseases, are a major contributor to blindness and
visual impairment in SSA. PSED, grouped together, was usually the second leading cause of blindness
after cataract, ranging as a proportion of blindness from 13 to 37%.
conclusions PSEDs are likely to grow in importance as causes of visual impairment and blindness
in SSA in the coming years as populations grow, age and become more urban in lifestyle. African-
based cohort studies are required to help estimate present and future needs and plan services to
prevent avoidable blindness.
keywords glaucoma, diabetic retinopathy, age-related macular degeneration, posterior segment eye
disease, prevalence, incidence, blindness, visual impairment, Africa
Introduction
Non-communicable diseases in low- and middle-income
countries
In recent decades, there has been a marked rise in life
expectancy that has contributed to a major epidemiologi-
cal shift in populations worldwide (Lopez et al. 2006).
These changes will increasingly lead to major public
health issues in low- and middle-income countries
(LMIC; Mathers & Loncar 2006). Current projections
suggest that non-communicable diseases (NCDs) will con-
tribute to two-thirds of global mortality by the year 2030
(Mathers & Loncar 2006). NCDs in LMIC have shown
substantial variation in prevalence, incidence, natural
history and risk factors compared with NCDs in popula-
tions in high-income countries (Boutayeb 2006).
Visual impairment and blindness
285 million people are visually impaired (VI) worldwide,
(severe visual impairment (SVI) defined as presenting
visual acuity (PVA) <6/60 but ≥3/60, moderate VI defined
as PVA <6/18 but ≥6/60) of whom 39 million are blind
(presenting visual acuity <3/60 in the better eye; Pascolini
& Mariotti 2012). Approximately 90% of those world-
wide with VI live in low-income countries. NCDs are the
leading causes of VI, in part due to the successful control
of infectious diseases. VI is ranked sixth in the top ten
causes of burden of disease in terms of disability-adjusted
life-years (DALYs) in low-income, middle-income and
high-income countries (Chiang et al. 2006). The sum of
DALYs from VI is 66 290 000 (4.3% of total), just
below HIV/AIDS at 71 460 000 (4.7%).
The number of people visually impaired in the World
Health Organization (WHO) African region is estimated
to be 26 million, of whom almost 6 million are blind.
This is based on estimates from population-based studies
in Botswana, Cameroon, Eritrea, Ethiopia, Gambia,
Ghana, Kenya, Mali, Nigeria, Rwanda, Uganda and Tan-
zania (Pascolini & Mariotti 2012). Despite Africa having
one of the highest prevalences of blindness, it is the most
underserved continent in terms of human resources
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available to treat and manage eye disease (Resnikoff
et al. 2012), with the greatest gap between existing need
and provision (Bastawrous & Hennig 2012).
In 2010, the WHO reported the leading causes of
visual impairment (VI) and blindness (Pascolini &
Mariotti 2012). Of these, three of the nine listed leading
causes are NCDs which are posterior segment in location,
(i.e. affecting the back of the eye). Posterior segment eye
disease (PSED) epidemiologically is commonly defined as
diseases of the retina, choroid and optic nerve and
primarily includes: glaucoma, age-related macular
degeneration (AMD) and diabetic retinopathy (DR).
These three conditions are the focus of this paper but do
not constitute all PSEDs. See Figure 1.
PSED and VISION2020
VISION2020 is the global initiative for the elimination of
avoidable blindness, launched in 1999, jointly by WHO
and the International Agency for the Prevention of Blind-
ness (IAPB) and provides technical support and advocacy
to prevention of blindness activities worldwide. It aims
over two decades to prevent 100 million people from
becoming blind.
VISION2020 has largely focused on the elimination of
anterior segment diseases, primarily cataract, as it alone
causes almost half of blindness and is amenable to cure
through surgery. VISION2020 has not focused on PSED
to date mostly due to a lack of data on the magnitude of
these conditions and lack of cost-effective treatment
options. This review aims to establish the magnitude of
visual impairment and blindness in SSA that can be
attributed to PSED.
Materials and methods
Our literature search was conducted for the years 1966
to September 2012 using PubMed. Keywords used
included the following: posterior segment eye disease,
glaucoma, age-related macular degeneration, diabetic
retinopathy, correctable visual impairment, preventable,
avoidable, Africa (MeSH), aphakia, blindness, visual
impairment, prevalence and population.
Studies were selected for inclusion if they were popula-
tion based, performed in sub-Saharan Africa with a sam-
ple size >1000, reported visual acuity impairment with its
causes, had a high participation rate (>80% of the tar-
geted sample) and presented results using the standard
WHO categories of VA. WHO definitions of visual
impairment are used (WHO/ICD-10 2007). We also
searched reference lists of studies meeting inclusion crite-
ria. Only published data were included.
All-cause prevalence (and 95% confidence interval
[CI]) of blindness, SVI and moderate VI was extracted
from each study, as well as the proportion of blindness,
SVI and moderate VI due to PSED (grouped or as single
diseases when available); then, the prevalence of blind-
ness, SVI and moderate VI due to PSED was calculated
from these estimates.
Results
Search results
In total, the initial search criteria identified 112 potential
manuscripts for inclusion. Review of the abstracts
reduced this to 39 potential studies, of which 17 sur-
veys, from 13 SSA countries, encompassing 88 067 indi-
viduals were included for analysis having fully met the
pre-specified search criteria. Data from the following
countries are presented: Burundi (Kandeke et al. 2012),
Cameroon (Oye et al. 2006; Oye & Kuper 2007), Eri-
trea (Muller et al. 2011), Ethiopia (Berhane et al. 2007),
Ghana (Budenz et al. 2012), Guinea (Moser et al.
2002), Kenya (Mathenge et al. 2007a, 2012), Malawi
(Kalua et al. 2011), Nigeria (Adegbehingbe et al. 2006;
Abdull et al. 2009), Rwanda (Mathenge et al. 2007b),
South Sudan (Ngondi et al. 2006), Tanzania (Kikira
Anterior segment Posterior segment
Cornea
Corneal opacity
Cataract
Refractive error Glaucoma
Diabetic retinopathy
Macula degeneration
Choroid
Retina
Optic nerve
Lens
Trachoma
Figure 1 Cross-sectional diagram of the
eye demonstrating the anterior and
posterior segments and their potential
diseases.
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2007; Habiyakire et al. 2010) and Uganda (Mbulaiteye
et al. 2002).
Posterior segment eye disease
Although PSEDs are frequently collated in SSA-based epi-
demiological studies and presented as a single entity or
group of conditions, they are clinically and pathophysio-
logical distinct. The most common methodological
approach deployed in SSA population-based studies, the
rapid assessment of avoidable blindness (RAAB; Dineen
et al. 2006), is not sufficiently sensitive to differentiate
posterior segment causes of low vision and hence
presented results are often collated.
Posterior segment eye disease in Africa
Cross-sectional population-based studies from the last
two decades performed in Africa have shown PSED to be
consistently the second (and occasionally the most com-
mon) leading cause of blindness. This includes studies
from Kenya (Mathenge et al. 2007a, 2012), Nigeria
(Rabiu & Muhammed 2008; Abdull et al. 2009), Tanza-
nia (Kikira 2007; Habiyakire et al. 2010), Rwanda
(Mathenge et al. 2007b), Cameroon (Oye et al. 2006;
Oye & Kuper 2007), Ghana (Guzek et al. 2005), Guinea
(Moser et al. 2002), Burundi (Kandeke et al. 2012) and
Ghana (Budenz et al. 2012; See Table 1). No longitudi-
nal data on PSED from population-based studies in
Africa have been published. A single cohort in Uganda
has 3-year cumulative incidence data on visual impair-
ment, (age-standardised incidence rate of 13.2, per 1000
PY) with AMD and glaucoma amongst the leading causes
of visual loss in new cases (Mbulaiteye et al. 2003).
However, no baseline clinical phenotyping data were col-
lected in eyes initially without visual impairment, so early
asymptomatic disease was not excluded.
The majority of available prevalence data in Africa
come from the rapid assessment of avoidable blindness
(RAAB) methodology (Dineen et al. 2006). Although
RAAB is a validated survey method (Mathenge et al.
2012), it has a limitation in common with more com-
prehensive surveys such as the Nigeria study (Dineen
et al. 2008) in that detailed eye examinations are only
performed in those found to have impairment of their
visual acuity. As glaucoma patients usually lose central
vision at the end stage of the disease, they are frequently
missed unless visual field assessment is performed. Fur-
thermore, ophthalmic assessment in RAAB relies on
direct ophthalmoscopy, constraining diagnostic accuracy,
so that the diseases are pragmatically grouped together
as one unit.
The majority of these surveys have used the WHO cod-
ing instructions, which use the ‘principal disorder respon-
sible for visual loss in the individual after considering
disorders in either eye which are most amenable to treat-
ment or prevention’ (World Health Organization 1988).
In other words, if a patient has PSED coexistent with cat-
aract, it will be deemed that cataract is the primary cause
of blindness/VI. Therefore, most VI prevalence data avail-
able in which cataract or refractive error is the primary
cause will underestimate the prevalence of PSED at all
levels of visual acuity.
Glaucoma in Africa
Prevalence. Current estimates suggest that there are 6.5
million people with glaucoma at all levels of vision in
sub-Saharan Africa (SSA) with a projected increase to 8.4
million in 2020 (Quigley & Broman 2006). Glaucoma is
estimated to be the second leading cause of blindness in
Africa (Cook 2009). These estimates undertaken by
Quigley and Broman (2006) are based on seven popula-
tion-based studies, of which two examined individuals of
African descent living outside of the African continent: in
Baltimore, USA (Leske et al. 1994) and Barbados (Tielsch
et al. 1991a) which has multiple limitations for inferring
data. Of the five based in Africa, three were undertaken
in South Africa (Salmon & Martell 1994; Rotchford &
Johnson 2002; Rotchford et al. 2003), one in Ghana
(Ntim-Amponsah et al. 2004) and one in Tanzania
(Buhrmann et al. 2000). The studies used varying sam-
pling methods and criteria for diagnosis of glaucoma.
No specific and sensitive test for glaucoma exists.
Current reference standard diagnosis requires expensive
visual field-testing equipment with expert interpretation
of the optic disc and visual field findings. Standardised
definitions and classifications of glaucoma in recent years
have allowed for better prevalence estimates and compar-
isons between populations (Foster et al. 2002).
Glaucoma may be congenital or acquired and further
subclassified into open-angle and closed-angle based on
the mechanism by which aqueous outflow from the eye is
compromised. The ‘angle’ refers to the junction between
cornea and iris, which forms an angle of varying degree
in each eye. Generally speaking, in glaucoma, when this
angle is large and the structures within it are visible on
clinical examination (gonioscopy), it is termed ‘open-
angle glaucoma’ and when these structures are limited or
not visible due to a narrow angle, it is termed ‘closed- or
narrow-angle glaucoma’ (Kanski 2007). Primary open-
angle glaucoma (POAG) disproportionately affects indi-
viduals of African descent (Quigley & Broman 2006)and
is difficult to diagnose in early disease, and when
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diagnosis is confirmed, there is still debate on the best
management in the context of limited resources and
prospects for long-term follow-up (Quigley et al. 2000).
Narrow-angle glaucoma prevalence is not well reported
in African populations, this is in large part due to gonios-
copy not being performed in the frequently used RAAB
methodology and also in other more comprehensive
surveys (Mathenge et al. 2012).
People of African descent (not living in Africa) have a
higher prevalence of glaucoma, are more likely to develop
glaucoma at an early age with more aggressive disease and
have a higher risk of glaucoma related blindness than Cau-
casians or Asians (Mason et al. 1989; Tielsch et al. 1991b).
It is therefore vital that the epidemiology of glaucoma is
investigated in more detail in various populations in Africa.
Comprehensive reviews on glaucoma in Africa were
published in 2009 (Cook 2009) and 2013 (Kyari et al.
2013), no new data from African population-based stud-
ies have since been published since 2009. The authors are
aware of awaited data to be published from study groups
in Nigeria (Dineen et al. 2008), Ghana and Kenya
(Mathenge et al. 2012).
Current data on glaucoma underestimate the true preva-
lence, as many cases of glaucoma have preservation of cen-
tral vision and do not include visual field assessment (Cook
2009). Furthermore, preferential coding of cataract due to
its reversible nature often means that glaucoma is not
assigned as the primary cause of blindness in a patient with
visual loss from coexistent glaucoma and lens opacity, as
per WHO criteria (World Health Organization 1988).
Incidence. It is assumed that incidence of glaucoma in
Africa will most closely reflect that of the Barbados Eye
Study, whose enrolled participants were of West African
descent (Leske et al. 2001, 2007). All other studies with
data on glaucoma incidence have been conducted in lar-
gely Caucasian populations: the Ponza Eye Study
(Cedrone et al. 2012), the Dalby Eye Study (Bengtsson
1991), the Blue Mountain Eye Study (Chandrasekaran
et al. 2006), the Melbourne Visual Impairment Study
(Dimitrov et al. 2003) and the Rotterdam Eye Study (de
Voogd et al. 2005). Annual incidence of new glaucoma
in these studies varied from 0.1 to 0.6%, the highest
being in the Barbados Eye Study which was largely made
up of people of African descent. To date, no data on
incident glaucoma or glaucoma progression from
population-based studies in Africa are available.
Diabetic retinopathy in Africa
Prevalence. Diabetes is a major threat to global public
health. The estimated prevalence of diabetes worldwide
was 285 million in 2010, representing 6.4% of the
world’s adult population, with a prediction that by 2030
there will be 438 million people with diabetes (DF 2009).
The most substantial increases (7 to 15 million, 111%)
are expected to be in Africa and the Middle East as a
result of various factors including population growth,
ageing, urbanisation, dietary changes and the increase in
obesity and sedentary lifestyles in these regions (King &
Herman 1998).
Although no data exist from population-based studies
(PBS) in Africa directly comparing ethnic variation as a risk
for DR, a hospital-based study in South Africa estimated
the prevalence of DR amongst patients with adult-onset
diabetes attending a large community hospital to be similar
in patients of African (37%), European (41%) or Indian
(37%) heritage. However, ‘severe DR’ (study specific clas-
sification) was significantly more frequent in Africans
(52%) and Indians (41%) than Europeans (26%; Kalk
et al. 1997). The predicted rise in proportion of adults
suffering from diabetes will inevitably lead to an increase
in the prevalence of DR (Williams et al. 2004).
The detection of DR in Africa remains a challenge in
part due to a lack of necessary equipment and skilled
manpower (Rotimi et al. 2003). The authors of this
review [also cited in reference: (Burgess et al. 2013)]
identified two high-quality, population-based, cross-sec-
tional studies reporting DR prevalence in Africa (but not
SSA). The Diabetes in Egypt project (1993; Herman et al.
1998) reported the proportion of DR and PDR in indi-
viduals with diabetes to be 31.6% and 0.9%, respec-
tively. The Mauritius diabetes complication study (Dowse
et al. 1998) reported 30.2% DR and 1.3% PDR; the
prevalence of PDR in subjects with known diabetes was
2.3%. These figures are comparable with prevalence esti-
mates reported in recent American and European studies.
Egypt and Mauritius are ethnically and demographi-
cally very different to most countries of sub-Saharan
Africa; the findings of these studies should be generalised
to other settings with caution.
There are also estimates of the prevalence of DR
amongst diabetics from high-quality clinic-based studies
in Africa. Very high prevalences of DR, PDR and macul-
opathy have been reported. A study from Malawi
reported 32.0% DR, 5.7% PDR, 15% sight-threatening
maculopathy (Glover et al. 2012). Two separate studies
from South Africa have found comparable results: Mash
et al. found 62.4% DR, 6.1% PDR and 15.2% with any
maculopathy (Mash et al. 2007); Rotchford et al. found
DR 40.3%, PDR 5.6%, 10.3% CSME (Rotchford 2002).
Evidence from unpublished data supports urbanisation
as a risk factor for DR. Slit-lamp assessment of the retina
assessing DR in a South-African PBS (Rotchford &
604 © 2014 The Authors. Tropical Medicine and International Health published by John Wiley & Sons Ltd.
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Johnson 2002; Rotchford et al. 2003) demonstrated a
0.7% prevalence of DR (NPDR 0.6%, PDR 0.1%) in
rural communities and a 2.1% prevalence of DR (NPDR
1.8%, PDR 0.3%) in urban communities (A. Rotchford,
unpublished data).
Estimates of the proportion of African patients with
diabetes who are visually impaired are high even com-
pared with older European and American studies. The
population-based Nigerian national blindness and visual
impairment survey was conducted between 2005 and
2007 (Abdull et al. 2009). DR was identified as the pri-
mary cause of visual impairment in 0.29% of 3129 sub-
jects with uncorrected VA worse than 6/12 and in 0.5%
of those with acuity less than 3/60. This study is likely to
underestimate the visual impact of DR as examiners were
instructed to preferentially record treatable, rather than
preventable, causes of visual impairment.
Incidence. No population-based cohort study was identi-
fied providing incidence data on DR in SSA. However,
two cohort studies of DR in Africa were identified by this
review, one of which was in SSA. A survey of diabetes
complications in Mauritius was followed up 6 years later
(Dowse et al. 1998). Of subjects with diabetes in the ini-
tial survey 40.5% were re-examined for DR (Tapp et al.
2006). Six-year incidence of DR was 23.8%. Duration of
diabetes and fasting blood glucose were independently
associated with incidence of retinopathy. Six-year pro-
gression to PDR was reported from no DR (0.4%), mild
NPDR (5.2%) and moderate NPDR (29.4%).
In South Africa, a cohort of patients with insulin-
dependent diabetes mellitus (IDDM) diagnosed before
age 30 years was followed up over time (Gill et al.
1984). In those subjects seen after 10 years of follow-up,
prevalence of DR had increased from 6% to 52% and
PDR from 0 to 3% (Gill et al. 1995). In subjects seen at
20 years, prevalence of DR had increased from 12% to
59%. No incidence data were collected (Gill et al. 2005).
No other prospective cohort studies were identified.
However, a study reflecting cumulative incidence of DR
from South Africa (Distiller et al. 2010) reported on 1520
type 1 and 8026 t ype 2 patients who had maintained
membership for ≥5 years in a community-based, privately
funded diabetes management programme. In type 1 partici-
pants, the prevalence of any retinopathy at baseline and at
5 years was 22.3% and 28.0%, respectively, and in type 2
participants 20.5% and 26.6%, respectively.
Age-related macular degeneration in Africa
Prevalence. The majority of data globally on AMD are
from Caucasians and Asian populations (Vingerling et al.
1996; Cruickshanks et al. 2001; Buch 2005; Buch et al.
2005; Munoz et al. 2005; Arnarsson et al. 2006; Chen
et al. 2008; Yasuda et al. 2009; Choudhury et al. 2011)
with a paucity of data from peoples of African descent.
Data on Africans are largely from studies undertaken in
African populations living outside of the African conti-
nent (Leske et al. 2004, 2007). Comparative data
between Caucasians and Africans living in the same geo-
graphical area have suggested differing predispositions
towards AMD (Sommer et al. 1991). A single popula-
tion-based study based in SSA (Kenya) determining the
prevalence of AMD was identified (Mathenge et al.
2013). Early and late AMD prevalence in adults aged
50 years and above was 11.2% and 1.2%, respectively,
amongst participants graded on digital retinal images
(n = 3,304). After controlling for age, women had a
higher prevalence of early AMD than men (odds ratio
1.5; 95% CI, 1.2–1.9), and the overall prevalence rose
significantly with each decade of age (Mathenge et al.
2013).
Incidence. The incidence of AMD has been reported in
population-based studies in the Americas, Australasia,
Europe, and Asia; however, no data exist from the Afri-
can continent to date. With the exceptions of the Latino
Eye Study (Varma et al. 2010) and the Barbados Eye
Study (Leske et al. 2004, 2006), all data are in Caucasian
populations, and inferred data from the Barbados study
suggest incident early AMD is similar to elsewhere in the
world, but late AMD is less common, possibly suggesting
a protective mechanism.
Discussion
We found through our review of the literature that
PSEDs are an important cause of vision loss in SSA coun-
tries. Selection bias may have led to information from
French- and Portuguese-speaking countries being omitted;
data from Egypt and Mauritius are unlikely to be repre-
sentative for the SSA, and data not in the peer-reviewed
literature were also omitted and may have been a source
of bias.
The detection of and treatment for PSED poses many
challenges to countries that currently lack the necessary
infrastructure and resources. VISION 2020 has placed
priority on conditions deemed more straightforward to
treat, and this strategy has proven largely successful.
PSEDs differ from the leading anterior segment eye dis-
eases (cataract and refractive error) in prevention/treat-
ment, as no cures currently exist (with the exception of
angle closure glaucoma). Surgical intervention can restore
vision in those visually impaired from cataract, and
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provision of glasses can restore or improve vision in peo-
ple with refractive error. However, established visual loss
from PSED is difficult to reverse, and for most condi-
tions, there is no ‘curative’ treatment.
Medical and/or surgical intervention for glaucoma can
slow disease progression and thereby reduce the risk of
further sight loss (Heijl et al. 2002). Systemic control of
diabetes mellitus, retinal laser treatment, intravitreal
injections and vitreoretinal surgery in sight-threatening
DR can stabilise and, to some degree, improve DR status
and thereby also prevent sight loss (1993). Currently no
cure for AMD exists, although intravitreal therapy is
available for end-stage wet AMD (approximately 10% of
all AMD cases). The infrastructure required to detect
AMD and deliver treatment as well as the cost of treat-
ment itself is currently prohibitively expensive for use in
most LMIC settings but is widely used in high-income
countries (Bowler et al. 2012). Vitamin supplementation
has shown some evidence of risk reduction in progression
of subtypes of AMD (Evans 2006), but not prevention of
AMD (Evans & Lawrenson 2012) and again may be
prohibitively expensive.
This review suggests that PSEDs account for a large
proportion of people with vision loss living in SSA. In
recent years, improved methodologies and understanding
may account for some increase in estimates of prevalence.
In particular, the affordable RAAB methodology (Dineen
et al. 2006) has led to increased numbers of researchers
undertaking population-based surveys in SSA.
The majority of existing data on NCDs, including
PSED, from LMIC are from cross-sectional studies pro-
viding valuable data on prevalence and risk factors. Lon-
gitudinal studies provide the opportunity to investigate
the natural history of diseases, which is necessary in
developing health policies at local and national levels.
Few longitudinal cohort studies from LMIC have been
conducted due to barriers including expense, complex
logistical planning and political challenges.
A change in the focus of programme managers and
policymakers over the coming decades is required if the
prevalence and incidence of PSED in SSA increases as
predicted. This increase is likely with extended life expec-
tancies and success of the VISION 2020 in the treatment
for anterior segment eye diseases and infectious diseases
of the eye. Urbanisation and westernised lifestyles may
also play a role in diseases such as diabetes and conse-
quently DR.
Many studies worldwide have collected cross -sectional
survey data on PSED prevalence; however, few studies
have data on incident PSED with no SSA-based eye dis-
ease cohort studies to date. The best estimates of inci-
dence for Africa are therefore extrapolated from studies
conducted elsewhere in the world. Furthermore, investi-
gating PSED in Africa offers a new perspective on
account of the different exposures and genetic make-up
of these populations compared with those studied thus
far, which may reveal new insights into the cause and
natural history of these diseases.
Inferring data from high-income countries undermines
efforts to establish studies in LMIC, which will guide the
effective use of minimal existing resources to deal with
the growing burden of NCDs.
Large, community-based cross-sectional and cohort
studies are needed to estimate prevalence of disease, risk
factors for disease, as well as incidence and progression
across Africa. Evidence for effectiveness and economics
of screening of and treatment for PSED in low resource
settings is vital for health service planners.
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